BioSpace News Archive

ICON plc, a world-leading healthcare intelligence and clinical research organisation, launched its “Optimising biotech funding” whitepaper.

Axonics, Inc., a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, reported preliminary unaudited revenue for the fourth quarter and fiscal year ended December 31, 2023.

Tryp Therapeutics, Inc. (“Tryp” or the “Company”) (CSE:TRYP)(OTCQB:TRYPF), a pioneering clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs,today announced a significant milestone in its clinical trial program for TRP-8803 (IV-infused psilocin).

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, highlighted its recent progress and outlined 2024 strategic priorities across its pipeline of mRNA cell therapy product candidates.

Anavex Life Sciences Corp. announced it was granted new U.S. Patent No. 11,839,600 entitled “NEURODEVELOPMENTAL DISORDER THERAPY” from the United States Patent and Trademark Office for its patent application number 17/890,083.

XOMA Corporation, the biotech royalty aggregator, announced the Board of Directors has named Owen Hughes as Chief Executive Officer and Jack L. Wyszomierski as Chairman of the Board.

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company) announced today that its SGX945 (dusquetide) development program for the treatment of oral lesions of Behçet’s Disease has received “Fast Track” designation from the U.S. Food and Drug Administration (FDA).

Rockwell Medical, Inc. announced that the Company amended its loan and security agreement with Innovatus Life Sciences Lending Fund I, LP.

Cabaletta Bio, Inc. announced that the U.S. Food and Drug Administration has granted separate Fast Track Designations to CABA-201, an investigational 4-1BB-containing fully human CD19-CAR T cell therapy, for the treatment of patients with dermatomyositis to improve disease activity and for the treatment of patients with systemic sclerosis to improve associated organ dysfunction.

Foghorn® Therapeutics Inc., a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, announced its strategic objectives for 2024.